Page 12 - HIV/AIDS Guidelines

HHS Panel on Antiretroviral Guidelines for Adults and
Adolescents Financial Disclosure (Last updated October 14, 2011; last

reviewed October 14, 2011)

Panel
Name Company Relationship
Status*
Joel E. Gallant M Bristol-Myers Squibb • Advisory Board
GlaxoSmithKline • Consultant
Gilead • Advisory Board, DSMB Member,
Research Support
Janssen Therapeutics • Advisory Board
(formerly Tibotec Therapeutics)
Merck • Advisory Board
RAPID Pharmaceuticals • Scientific Advisory Board
Sangamo Biosciences • DSMB Member
Stephen J. Gange M Merck • DSMB Member

Christopher M. Gordon M None N/A
Roy M. Gulick M Bristol-Myers Squibb • Consultant
Gilead • Consultant
GlaxoSmithKline/ViiV/Pfizer • Consultant, Research Support
Janssen Therapeutics • Consultant
(formerly Tibotec Therapeutics)
MedImmune • Consultant (ended May 2010)
Merck • Research Support, Consultant
ViroStatics • Consultant
W. Keith Henry M Gilead • Advisory Board, Research Support,
Speakers' Bureau, Honoraria, Consultant
GlaxoSmithKline/ViiV • Advisory Board, Research Support,
Speakers' Bureau, Honoraria, Consultant
Janssen Therapeutics • Research Support
(formerly Tibotec Therapeutics)
Martin S. Hirsch M Merck • Consultant
Tai-Med • DSMB Member
Michael D. Hughes M Boehringer Ingelheim • DSMB Member
Medicines Dev., Ltd. • DSMB Member
Janssen Therapeutics • DSMB Member
(formerly Tibotec Therapeutics)
Pfizer • DSMB Member
Virionyx Corp. Ltd. • DSMB Member
Jonathan Kaplan M None N/A

Bill G. Kapogiannis M None N/A

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents x

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.